Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years;~* ECOG PS 0-2;~* Histologically or cytologically documented unresectable and/or metastatic HCC;~* Measurable disease by RECIST criteria;~* Previous local therapy completed \> 6 weeks;~* Any acute toxicity (CTC-AE) \< grade 1;~* Child-Pugh A;~* Liver transaminases ≤ 5 x ULN;~* Albumin ≥ 2.8 g/dl;~* Serum total bilirubin ≤ 3 mg/dl;~* INR ≤ 2.3 or PT ≤ 6 seconds above control;~* WBC ≥ 3,000/µl;~* ANC ≥ 1,500/µl;~* Platelets ≥ 100,000/µl;~* Hb ≥ 8.5 g/dl;~* Creatinine ≤ 1.5 x ULN; AND~* Amylase and lipase \< 1.5 x ULN~Exclusion Criteria:~* Metastatic brain/leptomeningeal tumors;~* Prior or concomitant systemic anti-cancer treatment for HCC, including:~  * Systemic chemotherapy (TACE is allowed)~ * Immunotherapy~ * Hormonal therapy (hormonal therapy used for supportive used is allowed)~ * Raf-kinase inhibitors~ * MEK inhibitors~ * Farnesyl transferase inhibitors~ * VEGF/VEGFR- inhibitors or other anti-angiogenesis agents~ * Investigational anti-cancer agents~* Severe and/or uncontrolled medical conditions:~  * Uncontrolled high blood pressure~ * History of poor compliance with anti-hypertensive agents~ * Active or uncontrolled infection~ * Unstable angina~ * CHF~ * MI or CVA \< 6 months~ * GI bleeding \< 30 days~ * Unable to take oral medications~* Severe renal impairment which requires dialysis; proteinuria \> grade 2;~* BMT or stem cell rescue \< 4 months; organ transplant;~* HIV infection;~* Major surgical procedure, open biopsy, or significant traumatic injury \< 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 2 weeks;~* Receive central venous line placement within 7 days;~* Patients who anticipate receiving major surgery during the course of the study;~* Use rifampin, St. John's Wort \[Hypericum perforatum\];~* Patients taking narrow therapeutic index medications will be monitored closely. These include warfarin, phenytoin, quinidine, carbamazepine, phenobarbital, cyclosporine, and digoxin; OR~* Patients for whom tegafur is contra-indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).